GSK grabs $1.25B cash and a cut of Gilead’s megablockbuster Biktarvy sales as HIV rivals settle patent suit

Three years after ViiV Healthcare, the HIV specialist majority owned by GlaxoSmithKline, first sued Gilead over alleged patent infringement on one of its top drugs, the two companies have settled the case. Gilead will pay ViiV $1.25 billion in cash — while agreeing to set aside a 3% royalty on…

...

Click to view original post